CX 452
Latest Information Update: 04 Nov 2017
At a glance
- Originator Cutanix Corporation
- Class Nonsteroidal anti-inflammatories; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dermatitis; Rosacea
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Dermatitis in USA (Topical)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Rosacea in USA (Topical)
- 09 Apr 2003 Clinical trials in Dermatitis in USA (Topical)